BioMedNewsBreaks

ThursdayMay 22, 2025 3:34 pm

BioMedNewsBreaks — Soligenix Inc.’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results in Rare Cancer Trial

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is leading the way with innovative therapies for rare and difficult-to-treat diseases, particularly early-stage cutaneous T-cell lymphoma (“CTCL”), a rare form of cancer that affects the skin. “Soligenix’s proprietary treatment, HyBryte(TM), is currently in clinical trials, and the latest results have shown promising efficacy in treating CTCL,” reads a recent article. “‘Following 18 weeks of treatment, 75% of patients achieved ‘Treatment Success,’ reinforcing HyBryte(TM) as a potentially safe and fast-acting therapy for this chronic and underserved cancer,’ the company reported. The study results suggest that the treatment may be highly effective in reducing…

Continue Reading

ThursdayMay 22, 2025 3:08 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) RTNova Shows Promise in Targeted Tumor Therapy

Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors. The innovative platform not only targets cancer cells effectively but also minimizes harm to surrounding healthy tissues, potentially improving treatment outcomes and reducing side effects. As global cancer rates continue to rise, Calidi’s RTNova platform and tumor-specific virotherapy hold the promise of offering new hope to cancer patients, addressing the limitations of existing treatments, and potentially improving survival rates across multiple cancer types. The company’s ongoing research and deep commitment to scientific excellence position…

Continue Reading

ThursdayMay 22, 2025 10:18 am

BioMedNewsBreaks — Intelligent Bio Solutions Inc. (NASDAQ: INBS) to Showcase Fingerprint Drug Testing at RISE25 Conference

Intelligent Bio Solutions (NASDAQ: INBS) announced its participation at the RISE25 conference in Kissimmee, Florida, from May 28 to 31, 2025, where it will support U.S. distribution partner SMARTOX. INBS will demonstrate its Intelligent Fingerprinting Drug Screening System—a non-invasive, rapid test using fingerprint sweat to detect substances like THC, cocaine, methamphetamine, and opiates. With results delivered in under ten minutes, the technology is well-suited for treatment courts and justice applications. INBS views the event as a key platform to engage stakeholders as it advances toward U.S. market entry.  To view the full article, visit https://ibn.fm/ml0S2  About Intelligent Bio Solutions Inc. …

Continue Reading

WednesdayMay 21, 2025 9:00 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at Wall Street Conference on May 21

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that Founder and CEO Dr. Jonathan Javitt will deliver a company update at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida. NRx is one of six companies invited to present at the high-profile event, which is expected to draw more than 1,000 attendees representing over $1 trillion in investment capital. The presentation will highlight the company’s progress toward FDA approval of NRX-100, a preservative-free intravenous ketamine formulation, as well as its strategic acquisition plans for HOPE clinics focused on treating suicidal depression, PTSD, and related conditions. To…

Continue Reading

TuesdayMay 20, 2025 9:30 am

BioMedNewsBreaks — VERAXA Biotech AG Appoints Dr. Rick Austin as Chief Scientific Officer

VERAXA Biotech AG, a cancer therapy innovator, and proposed de-SPAC target of Voyager Acquisition Corp. (NASDAQ: VACH), announced the appointment of Rick Austin, Ph.D., as Chief Scientific Officer, effective May 1. Dr. Austin brings more than 25 years of oncology research and development leadership and will help drive VERAXA’s BiTAC(TM) platform and clinical-stage pipeline. He previously served as VP of Research at Harpoon Therapeutics (acquired by Merck in 2024) and held key roles at Amgen and Tularik, contributing to the development of BiTE(R) technologies. Dr. Austin holds a Ph.D. from Yale and has led numerous IND filings, authored over 25…

Continue Reading

TuesdayMay 20, 2025 9:20 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Named Exclusive UK and EEA Distributor for ZOLEO Satellite Devices

NextPlat (NASDAQ: NXPL, NXPLW) announced that its subsidiary, Global Telesat Communications Ltd (GTC), has been appointed the exclusive distributor for ZOLEO Inc. across the UK and European Economic Area. ZOLEO's flagship global satellite communicator extends smartphone messaging coverage via the Iridium(R) satellite network and has earned accolades including Outdoor Retailer’s Innovation Award "Product of the Year." The partnership adds to GTC’s expanding e-commerce and Amazon storefront portfolio of satellite connectivity solutions for remote workers, outdoor enthusiasts, and global travelers. To view the full press release, visit: https://ibn.fm/U2bRq About NextPlat Corp NextPlat is a global e-commerce platform company created to capitalize…

Continue Reading

MondayMay 19, 2025 9:41 am

BioMedNewsBreaks — Intelligent Bio Solutions Inc. (Nasdaq: INBS) Expands Remote Workforce Testing with Fingerprint Drug Screening in Australia

Intelligent Bio Solutions (Nasdaq: INBS), a medical technology company focused on rapid, non-invasive testing, successfully completed a full workforce drug screening for Barcaldine Regional Council in Queensland, Australia, using its Intelligent Fingerprinting Drug Screening System. Over 160 employees were tested and cleared within 90 minutes, significantly reducing operational disruption compared to traditional methods. The on-site, fingerprint-based solution enabled same-day results and supported immediate workforce return, highlighting INBS' growing presence in regional and remote testing markets.  To view the full article, visit https://ibn.fm/rJhhJ  About Intelligent Bio Solutions Inc.  Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid,…

Continue Reading

FridayMay 16, 2025 11:27 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q1 Loss, Highlights Progress on TPI 287 for Brain Cancer

CNS Pharmaceuticals (NASDAQ: CNSP) reported a Q1 2025 net loss of $4.3 million, up from $3.5 million in the prior year period, as R&D spending increased to support data analysis for its Berubicin trial. The company remains focused on advancing TPI 287, a novel taxane with the potential to treat glioblastoma by crossing the blood-brain barrier. CNS has secured Orphan Drug Designation for TPI 287 and plans to initiate a Phase 2 study in recurrent GBM by late 2025. With $13.1 million in cash at quarter-end and an additional $5 million raised in May, the company expects to fund operations…

Continue Reading

FridayMay 16, 2025 9:00 am

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress on Ketamine NDA and HOPE Clinic Rollup 

NRx Pharmaceuticals (NASDAQ: NRXP) reported a Q1 2025 net loss of $5.5 million, down from $6.5 million in the same period last year, with operating losses narrowing to $3.8 million. The company advanced regulatory and commercial milestones for its two lead programs: NRX-100, a preservative-free IV ketamine formulation for suicidal depression now supported by an NDA fee waiver and new patent filing; and NRX-101, an oral treatment for bipolar depression with a PDUFA date anticipated before year-end. Subsidiary HOPE Therapeutics also gained momentum with $10.3 million in new acquisition funding to support a national psychiatry clinic rollup. NRx ended the…

Continue Reading

ThursdayMay 15, 2025 3:35 pm

BioMedNewsBreaks — Adageis’ Fintech Platform Drives Smarter, More Profitable Healthcare

Adageis, a forward-thinking healthcare technology company, is empowering clinics and medical groups to succeed in the shift from fee-for-service to value-based care through its AI-powered platform. The company’s ProActive Care solution deciphers complex insurance contracts, integrates with leading EHR systems, and offers real-time analytics to help providers track revenue trends as well as their performance and profitability. Proprietary components of the platform, including the Value-Based Care Engine and Patented Risk Engine, identify care gaps and high-risk patients, enabling earlier interventions that enhance both clinical and financial performance. By developing targeted solutions, with a focus on smaller and independent practices, Adageis…

Continue Reading